Search research articles
Contact Us
Filters
Showing results (51-60 of 84) with videos related to
Page
of 9
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 19, 2008
Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer
Jim Cassidy, Stephen Clarke, Eduardo Díaz-Rubio, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 19, 2008
Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study
Leonard B Saltz, Stephen Clarke, Eduardo Díaz-Rubio, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 17, 2023
Bevacizumab in Combination With Oxaliplatin-Based Chemotherapy As First-Line Therapy in Metastatic Colorectal Cancer: A Randomized Phase III Study
Leonard B Saltz, Stephen Clarke, Eduardo Díaz-Rubio, et al.
The Oncologist
|
January 14, 2015
Prognostic factors of survival in a randomized phase III trial (MPACT) of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone in patients with metastatic pancreatic cancer
Josep Tabernero, E Gabriela Chiorean, Jeffrey R Infante, et al.
Anti-Cancer Drugs
|
July 9, 2020
Predictive and prognostic value of magnesium serum level in FOLFIRI plus cetuximab or bevacizumab treated patients with stage IV colorectal cancer: results from the FIRE-3 (AIO KRK-0306) study
Christoph Schulz, Volker Heinemann, Kathrin Heinrich, et al.
Journal of the National Cancer Institute
|
February 2, 2015
nab-Paclitaxel plus gemcitabine for metastatic pancreatic cancer: long-term survival from a phase III trial
David Goldstein, Robert Hassan El-Maraghi, Pascal Hammel, et al.
European Radiology
|
August 17, 2022
Standard diametric versus volumetric early tumor shrinkage as a predictor of survival in metastatic colorectal cancer: subgroup findings of the randomized, open-label phase III trial FIRE-3 / AIO KRK-0306
Felix O Hofmann, Volker Heinemann, Melvin D'Anastasi, et al.
Oncotarget
|
December 30, 2017
Exploring the effect of primary tumor sidedness on therapeutic efficacy across treatment lines in patients with metastatic colorectal cancer: analysis of FIRE-3 (AIOKRK0306)
Dominik Paul Modest, Sebastian Stintzing, Ludwig Fischer von Weikersthal, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 1, 2007
Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer: a randomized, multicenter, phase III trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group
Richard Herrmann, György Bodoky, Thomas Ruhstaller, et al.
World Journal of Gastroenterology
|
July 2, 2010
Cetuximab plus FOLFOX6 or FOLFIRI in metastatic colorectal cancer: CECOG trial
Janja Ocvirk, Thomas Brodowicz, Fritz Wrba, et al.
Page
of 9
Search research articles
Search
Showing results (51-60 of 84) with videos related to
Sort By:
Page
of 9
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 19, 2008
Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer
Jim Cassidy, Stephen Clarke, Eduardo Díaz-Rubio, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 19, 2008
Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study
Leonard B Saltz, Stephen Clarke, Eduardo Díaz-Rubio, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 17, 2023
Bevacizumab in Combination With Oxaliplatin-Based Chemotherapy As First-Line Therapy in Metastatic Colorectal Cancer: A Randomized Phase III Study
Leonard B Saltz, Stephen Clarke, Eduardo Díaz-Rubio, et al.
The Oncologist
|
January 14, 2015
Prognostic factors of survival in a randomized phase III trial (MPACT) of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone in patients with metastatic pancreatic cancer
Josep Tabernero, E Gabriela Chiorean, Jeffrey R Infante, et al.
Anti-Cancer Drugs
|
July 9, 2020
Predictive and prognostic value of magnesium serum level in FOLFIRI plus cetuximab or bevacizumab treated patients with stage IV colorectal cancer: results from the FIRE-3 (AIO KRK-0306) study
Christoph Schulz, Volker Heinemann, Kathrin Heinrich, et al.
Journal of the National Cancer Institute
|
February 2, 2015
nab-Paclitaxel plus gemcitabine for metastatic pancreatic cancer: long-term survival from a phase III trial
David Goldstein, Robert Hassan El-Maraghi, Pascal Hammel, et al.
European Radiology
|
August 17, 2022
Standard diametric versus volumetric early tumor shrinkage as a predictor of survival in metastatic colorectal cancer: subgroup findings of the randomized, open-label phase III trial FIRE-3 / AIO KRK-0306
Felix O Hofmann, Volker Heinemann, Melvin D'Anastasi, et al.
Oncotarget
|
December 30, 2017
Exploring the effect of primary tumor sidedness on therapeutic efficacy across treatment lines in patients with metastatic colorectal cancer: analysis of FIRE-3 (AIOKRK0306)
Dominik Paul Modest, Sebastian Stintzing, Ludwig Fischer von Weikersthal, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 1, 2007
Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer: a randomized, multicenter, phase III trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group
Richard Herrmann, György Bodoky, Thomas Ruhstaller, et al.
World Journal of Gastroenterology
|
July 2, 2010
Cetuximab plus FOLFOX6 or FOLFIRI in metastatic colorectal cancer: CECOG trial
Janja Ocvirk, Thomas Brodowicz, Fritz Wrba, et al.
Page
of 9